Occult hepatitis B virus infection in patients with chronic liver disease due to hepatitis C virus and hepatocellular carcinoma in Brazil

Arquivos de Gastroenterologia

Volumn 44, Issue 1, 2007, Pages 58-63

  Branco, Fernanda ^a,c   De Mattos, Angelo Alves ^a   Coral, Gabriela Perdomo ^a   Vanderborght, Bart ^b   Santos, Diogo Edele ^a   França, Paulo ^b   Alexandre, Cláudio ^a  

^a Gastroenterology and Hepatology Service   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c NONE   (Brazil)

Author keywords

Carcinoma, hepatocellular; Hepatitis B virus; Hepatitis C virus; Liver diseases

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; VIRUS DNA;

ADULT; ARTICLE; BRAZIL; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL CARCINOMA; MALE; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PREVALENCE; SERUM;

EID: 34447512864     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/s0004-28032007000100013     Document Type: Article

References (41)

1. Acharya SK. Occult hepatitis B infection: the enigmatic virus. Indian J Gastroenterol. 2003;22:121-3.
2. Agarwal N, Naik S, Aggarwal R, Singh H, Somani Sk, Kini D. Occult hepatitis B virus infection as a cause of cirrhosis of liver in a region with intermediate endemicity. Indian J Gastroenterol. 2003;22:127-31.
3. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The Metavir Cooperative Study Group. Hepatology. 1996;24:289-93.
4. Berasain C, Betes M, Panizo A, Ruiz J, Herrero JI, Civeira MP. Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut. 2000;47:429-35.
5. Bowden S, Bartholomeusz A, Locarnini S. Lamivudine resistant occult HBV: implications for public health? J Hepatol. 2003;38:526-8.
6. Brechot C, Degos F, Lugassy C, Thiers V, Zafrani S, Franco D. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med. 1985;312:270-6.
7. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology. 2001;34:194-203.
8. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-30.
9. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando Me, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999;341:22-6.
10. Chan HL, Tsang SW, Leung NW, Tse CH, Hui Y, Tam JS. Occult HBV infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection. Am J Gastroenterol. 2002;97:1211-5.
11. Chemin I, Jeantet D, Kay A, Trepo C. Role of silent hepatitis B virus in chronic hepatitis B surface antigen(-) liver disease. Antiviral Res. 2001;52:117-23.
12. Fabris P, Brown D, Tositti G, Bozzola L, Giordani MT, Bevilacqua P. Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C. J Clin Virol. 2004;29:160-6.
13. Fukuda R, Ishimura N, Niigaki M, Hamamoto S, Satoh S, Tanaka S. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol. 1999;58:201-7.
14. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med. 2004;350:1118-29.
15. Georgiadou SP, Zachou K, Rigopoulou E, Liaskos C, Mina P, Gerovasilis F, Makri E, Dalekos GN. Occult hepatitis B virus infection in greek patients with chronic hepatitis C and in patients with diverse nonviral hepatic diseases. J Viral Hepat. 2004,11:358-65.
16. Giannini E, Ceppa P, Botta F, Fasoli A, Romagnoli P, Ansaldi F. Previous hepatitis B virus infection is associated with worse disease stage and occult hepatitis B virus infection has low prevalence and pathogenicity in hepatitis C virus-positive patients. Liver Int. 2003;23:12-8.
17. Han KH, Hollinger FB, Noonan CA, Solomon H, Klintmalm GB, Genta RM. Southern-blot analysis and simultaneous in situ detection of hepatitis B virus-associated DNA and antigens in patients with end-stage liver disease. Hepatology. 1993;18:1032-8.
18. Haushofer AC, Hauer R, Brunner H, Koller U, Trubert-Exinger D, Halbmayer WM. No evidence of hepatitis B virus activity in patients with anti-HBc antibody positivity with or without anti-hepatitis C virus antibody positivity. J Clin Virol. 2004;29:221-3.
19. Hoofnagle JH, Seeff LB, Bales ZB, Zimmerman HJ. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med. 1978;298:1379-83.
20. Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat. 2002;9:243-57.
21. Kao JH, Chen PJ, Lai MY, Chen DS. Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol. 2002;40:4068-71.
22. Kazemi-Shirazi L, Petermann D, Muller C. Hepatitis B virus DNA in sera and liver tissue of HBsAg negative patients with chronic hepatitis C. J Hepatol. 2000;33:785-90.
23. Komori M, Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A. Long-term clinical impact of occult hepatitis B virus infection in chronic hepatitis B patients. J Hepatol. 2001;35:798-804.
24. Kubo S, Tamori A, Ohba K, Shuto T, Yamamoto T, Tanaka H. Previous or occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma without hepatic fibrosis. Dig Dis Sci. 2001;46:2408-14.
25. Liver Cancer Study Group of Japan, editors. Classification of primary liver cancer. Tokyo: Kanehara Shuppan; 1997. p.1-22.
26. Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. J Hepatol. 2003;38 Suppl 1:s136-s49.
27. Lyra LGC. Hepatite pelo vírus B. In: Mattos AA, Dantas W, ed. Compêndio de hepatologia. 2.ed. São Paulo: Fundo Editorial Bik, 2001. p.471-87.
28. Mariscal LF, Rodriguez-Inigo E, Bartolome J, Castillo I, Ortiz-Movilla N, Navacerrada C. Hepatitis B infection of the liver in chronic hepatitis C without detectable hepatitis B virus DNA in serum. J Med Virol. 2004;73:177-86.
29. McOmish F, Yap PL, Dow BC, Follett EA, Seed C, Keller AJ. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol. 1994;32:884-92.
30. Niigaki M, Fukuda R, Hamamoto S, Ishimura N, Ishihara S, Akagi S. Role of hepatitis B virus in non-B, non-C chronic liver disease: in vitro proliferation and interferon-gamma production of peripheral blood mononuclear cells in response to hepatitis B core antigen and its relation to hepatitis activity. Am J Gastroenterol. 2000;95:239-47.
31. Pal J, Somogyi C, Szmolenszky AA, Szekeres G, Sipos J, Hegedus G. Immunohistochemical assessment and prognostic value of hepatitis B virus x protein in chronic hepatitis and primary hepatocellular carcinomas using anti-HBxAg monoclonal antibody. Pathol Oncol Res. 2001;7:178-84.
32. Paterlini P, Gerken G, Nakajima E, Terre S, D'Errico A, Grigioni W. Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen. N Engl J Med. 1990;323:80-5.
33. Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology. 2000;32:654-9.
34. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Crax A. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology. 2004;126:102-10.
35. Sagnelli E, Coppola N, Scolastico C, Filippini P, Santantonio T, Stroffolini T. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology. 2000;32:1106-10.
36. Sagnelli E, Coppola N, Scolastico C, Mogavero Ar, Filippini P, Piccinino F. HCV genotype and "silent" HBV coinfection: two main risk factors for a more severe liver disease. J Med Virol. 2001;64:350-5.
37. Sheu JC, Huang GT, Shih LN, Lee WC, Chou HC, Wang JT. Hepatitis C and B viruses in hepatitis B surface antigen-negative hepatocellular carcinoma. Gastroenterology. 1992;103:1322-7.
38. Shintani Y, Yotsuyanagi H, Moriya K, Fujie H, Tsutsumi T, Takayama T. The significance of hepatitis B virus DNA detected in hepatocellular carcinoma of patients with hepatitis C. Cancer. 2000;88:2478-86.
39. Souto FJD. Distribuição da hepatite B no Brasil: atualização do mapa epidemiológico e proposiçõ es para seu controle. GED Gastroenterol Endosc Dig. 1999;18:143-50.
40. Squadrito G, Orlando ME, Pollicino T, Raffa G, Restuccia T, Cacciola I. Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection. Am J Gastroenterol. 2002;97:1518-23.
41. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis. 2002;2:479-86.